Effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray on clinical signs and quality of life of patients with streptococcal tonsillopharyngitis: multicentre, prospective, randomised, double-blinded, placebo-controlled study

Basit Öğe Kaydı
dc.contributor.authorCingi, C.
dc.contributor.authorSongu, M.
dc.contributor.authorUral, A.
dc.contributor.authorErdogmus, N.
dc.contributor.authorYildirim, M.
dc.contributor.authorCakli, H.
dc.contributor.authorBal, C.
dc.date.accessioned2024-04-24T16:19:03Z
dc.date.available2024-04-24T16:19:03Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: To assess the effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray, used in conjunction with antibiotic treatment, on the intensity of clinical signs and quality of life of patients with group A streptococcal tonsillopharyngitis. Methods: Patients (n = 147) with streptococcal tonsillopharyngitis were recruited and randomly allocated to either the treatment group (penicillin plus chlorhexidine and benzydamine; n = 72) or control group (penicillin plus placebo; n = 75). Blinded assessments were conducted before and after 10 days' treatment, using an intensity rating scale for clinical sign severity, a visual analogue scale for subjective health state, the Short Form 36 Health Questionnaire for quality of life, and a customised questionnaire for side effects. Results: The treatment group showed a statistically significant reduction in the intensity of clinical signs, compared with the control group. On treatment day 7, there was no significant difference in quality of life between the treatment and control groups. The treatment drugs were well tolerated, and no serious adverse events were observed. Conclusion: Chlorhexidine gluconate and benzydamine hydrochloride mouth spray, added to standard antibiotic treatment, significantly alleviate the intensity of clinical signs in patients with streptococcal pharyngitis. Further research is needed using larger sample sizes or alternative control groups.en_US
dc.identifier.doi10.1017/S0022215111000065
dc.identifier.endpage625en_US
dc.identifier.issn0022-2151
dc.identifier.issn1748-5460
dc.identifier.issue6en_US
dc.identifier.pmid21310101
dc.identifier.scopus2-s2.0-79958793705
dc.identifier.scopusqualityQ2
dc.identifier.startpage620en_US
dc.identifier.urihttps://doi.org/10.1017/S0022215111000065
dc.identifier.urihttps://hdl.handle.net/11468/16381
dc.identifier.volume125en_US
dc.identifier.wosWOS:000292101800015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherCambridge Univ Pressen_US
dc.relation.ispartofJournal of Laryngology and Otology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPharyngitisen_US
dc.subjectTonsillitisen_US
dc.subjectChlorhexidineen_US
dc.subjectBenzydamineen_US
dc.subjectTherapeuticsen_US
dc.titleEffect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray on clinical signs and quality of life of patients with streptococcal tonsillopharyngitis: multicentre, prospective, randomised, double-blinded, placebo-controlled studyen_US
dc.titleEffect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray on clinical signs and quality of life of patients with streptococcal tonsillopharyngitis: multicentre, prospective, randomised, double-blinded, placebo-controlled study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu